Market Herald logo

Subscribe

Be the first with the news that moves the market
  • PharmaDrug Inc. (PHRX) has entered into a clinical trial agreement with The John Hopkins University to evaluate DMT in a comparative clinical study
  • The clinical study will use a variety of assessment tools to understand how DMT acts in the brain of healthy volunteers
  • Ultimately, the goal is to be able to apply this knowledge in tailoring the treatment of serious neuropsychiatric conditions
  • PharmaDrug is a specialty pharmaceutical company focused on the research, development and commercialization of controlled substances and natural medicines
  • PharmaDrug Inc. (PHRX) opened trading at $0.05 per share

PharmaDrug Inc (PHRX) has entered into an agreement with The John Hopkins University to evaluate N-Dimethyltryptamine (DMT) in a clinical study.

Led by principal investigator Dr. Frederick S. Barrett, associate professor of Psychiatry and Behavioral Sciences at John Hopkins, the clinical study will use a variety of assessment tools to understand how DMT acts in the brain of healthy volunteers.

The dramatic mind-altering effects of these drugs is well known, and as such, a study volunteer’s expectancy may contribute to clinical outcomes.

To address this common study design limitation, PharmaDrug has sponsored the submission of an Investigational New Drug application to the United States FDA, which aims to compare the effects of DMT with another potently psychotropic drug.

Dr. Barrett will be supported by co-investigators Dr. Sandeep Nayak and Dr. Roland Griffiths from the JHU Center for Psychedelic and Consciousness Research.

Daniel Cohen, CEO of PharmaDrug, commented on the study.

“We are excited to collaborate and support Dr. Frederick Barrett to better understand DMT and its potential,” he said. “We are very grateful to partner with them to achieve our objectives in expanding our pharmaceutical product pipeline for novel uses and delivery forms of DMT to treat unmet medical needs.”

The first part of the planned study will examine the dose effects of DMT and the other test article.

During the second part of the study, healthy subjects will be exposed to a maximum tolerated dose of each drug, as defined in part one of the study.

Ultimately, the goal is to be able to apply this knowledge in tailoring the treatment of serious neuropsychiatric conditions.

PharmaDrug is a specialty pharmaceutical company focused on the research, development and commercialization of controlled substances and natural medicines.

PharmaDrug Inc. (PHRX) opened trading at $0.05 per share.

More From The Market Herald

" Hemostemix (TSXV:HEM) announces non-brokered private placement

Hemostemix (HEM) has announced a non-brokered private placement of up to 15 million units.
WELL Health - Chairman & CEO Hamed Shahbazi

" WELL Health (TSX:WELL) closes $34.5M public offering

WELL Health Technologies Corp. (WELL) has completed a bought deal public offering for proceeds of $34.5 million.

" Simply Better Brands (TSXV:SBBC) enters the weight loss category

Simply Better Brands (SBBC) has launched its entry into the weight loss category with a PureKana Keto Gummy.

" Cardiol Therapeutics (TSX:CRDL) appoints new directors

Cardiol Therapeutics (CRDL) has appointed Teri Loxam and Chris Waddick to its Board of Directors, effective immediately.